At a glance
Swissmedic is Switzerland’s national therapeutic-products authority. EMA performs scientific assessment and coordination within the EU system, while the European Commission grants centrally authorised medicines legal effect across EU member states. An EU authorisation does not itself authorise sale in Switzerland. It can support a Swissmedic application, including an Article 13 reliance route when its conditions are met, but the company still needs a Swiss applicant and holder, Swiss documentation, local safety and supply arrangements, and a separate reimbursement strategy.
Key takeaways
- EMA assessment and an EU decision do not create a Swiss authorisation.
- Article 13 can use foreign assessment work, but Swissmedic retains the Swiss decision.
- The Swiss holder, establishment licences, product information, PV and release model need their own evidence.
- Swissmedic authorisation and FOPH reimbursement are separate decisions.
Who decides what in the EU and Switzerland?
Swissmedic authorises and supervises therapeutic products for Switzerland under Swiss law. In the EU centralised procedure, EMA’s scientific committees assess quality, safety and efficacy and issue an opinion; the European Commission then makes the legally binding authorisation decision. National and other EU routes also exist, so “EMA-approved” is often imprecise. For a Swiss plan, record the exact foreign procedure, decision maker, legal decision, approved texts and assessment reports rather than relying on the shorthand.
Does an EU authorisation apply in Switzerland?
No. Switzerland is outside the EU marketing-authorisation system, and a central EU authorisation has no automatic Swiss legal effect. The product still needs Swissmedic authorisation before ordinary Swiss placing on the market. This distinction also affects lifecycle control: the Swiss authorisation has its own approved indication, product information, conditions and variation history. A team should therefore maintain a Swiss decision record and compare it continuously with the reference market instead of treating Switzerland as another EU country code.
How can Article 13 reliance use an EU assessment?
Article 13 of the Therapeutic Products Act allows Swissmedic to take account of results from a country with a comparable medicines-control system when the statutory conditions and current guidance are met. The applicant must request the route and provide the final foreign decision, current assessment report and full documentation. Swissmedic checks comparability, Swiss-specific requirements and the current lifecycle, and it can conduct its own review. Reliance is therefore a route choice, not mutual recognition, automatic conversion or a guarantee of reduced questions.
- Identify the exact reference authority and final decision.
- Reconcile the approved indication, strength, form, sites and manufacturing process.
- Include later foreign variations and relevant authority correspondence.
- Explain negative, withdrawn, suspended or materially different decisions.
Who may apply and hold the Swiss authorisation?
The Swiss applicant must satisfy Article 10 TPA, including a registered address, registered office or branch in Switzerland and the required authorisation to manufacture, import or conduct wholesale trade. This creates a local legal and operating decision that EU authorisation does not solve. The same entity does not have to perform every task, but outsourced import, storage, pharmacovigilance or regulatory operations need appropriate licensed parties, written responsibilities, access to records and holder oversight. A distributor is the MAH only if it is the named eligible holder, not simply because it sells the product.
Sources and further reading: [1]
What changes in the dossier, labelling and lifecycle?
A usable EU CTD can supply much of the scientific core, but a Swiss submission still needs its route-specific administrative package, Swiss Module 1, the requested reference-authority material and a reconciled eCTD lifecycle. Swiss professional information must be provided in German, French and Italian under current guidance, and the holder is responsible for accurate translations; packaging follows separate Swiss rules and language conditions. After authorisation, Swiss variations, safety changes and supply changes must be assessed against the Swiss record. Copying the newest EU text without a Swiss change assessment can create a mismatch rather than compliance.
What local PV, supply and reimbursement work remains?
The Swiss MAH needs a functioning pharmacovigilance system, a qualified responsible person and deputy, documented Swiss interfaces and oversight of any provider. It also needs an establishment-licence and market-release model covering the importer, Responsible Person, distribution and recall chain. These roles are distinct from the EU QPPV and manufacturing QP titles even when one individual or global system supports more than one market. Finally, Swissmedic authorisation does not place a medicine on the FOPH Specialities List. Outpatient reimbursement requires a separate assessment of effectiveness, appropriateness and economic efficiency, including price comparisons and any limitation.
Which EU-to-Switzerland gaps should the team close?
Use the table as a working gap map, not as an authority checklist. For each row, identify the current evidence, the Swiss owner, the decision still needed and the controlled record that will prove closure. This prevents teams from focusing only on the submission while local legal ownership, safety, release or access remains unresolved.
| Question | EMA and EU system | Swissmedic and Switzerland | Manufacturer action |
|---|---|---|---|
| Legal effect | Commission decision applies within its EU scope | Swissmedic decision applies in Switzerland | Plan a separate Swiss application |
| Assessment use | EMA assessment report supports the EU decision | May be considered under Article 13 when conditions are met | Secure final and current reference documents |
| Holder | EU rules define the eligible holder | Article 10 TPA requires Swiss presence and relevant licence | Select the exact Swiss entity |
| Dossier and text | EU administrative package and approved EU texts | Swiss Module 1 and Swiss-approved multilingual information | Run a documented gap and translation review |
| Safety | EU QPPV and EU system requirements | Swiss RPV, deputy and Swiss reporting interfaces | Map responsibilities and oversight |
| Supply | EU manufacturing and distribution controls | Swiss licence scope and MAH market-release model | Map importer, RP, records and recall |
| Patient access | EU authorisation is not one EU reimbursement decision | FOPH decides Specialities List admission separately | Build the Swiss value and price workstream |
MAH / CH
EU-to-Switzerland gap checklist
Use this worksheet to prepare a focused route discussion without sending a confidential dossier.
- Exact EU procedure, decision and current assessment report
- Swiss route hypothesis and Article 13 comparability check
- Eligible Swiss applicant and holder model
- Swiss Module 1 and eCTD lifecycle gap list
- German, French and Italian product-information plan
- Swiss RPV, deputy and safety-system interfaces
- Importer, market-release RP and distribution map
- Separate FOPH reimbursement and pricing strategy
Continue exploring
Switzerland vs EUQuestions before your next step
Is Swissmedic a government agency?
Swissmedic is the Swiss Agency for Therapeutic Products, a federal public-law institution responsible for therapeutic-product authorisation and surveillance under Swiss law. Its decisions apply to Switzerland.
Is EMA the authority that grants every EU medicine authorisation?
No. In the centralised procedure EMA conducts the scientific assessment and gives an opinion, while the European Commission issues the binding decision. Other EU authorisation routes also involve national authorities.
Can Swissmedic accept an EMA dossier without changes?
A current EU dossier can be a strong foundation, but Swiss Module 1, Swiss product information, reference-authority records, lifecycle reconciliation and product-specific gaps remain. The required package depends on the Swiss route and product.
Does Article 13 guarantee a faster Swiss decision?
No. Article 13 permits Swissmedic to consider foreign assessment results when its conditions are met. Swissmedic retains discretion over the Swiss review, and route suitability depends on complete, comparable and current evidence.
Does Swissmedic authorisation include reimbursement?
No. Swissmedic decides product authorisation. The FOPH separately decides admission to the Specialities List and the reimbursed maximum price for compulsory outpatient insurance.
Sources and further reading
- Swiss Confederation: Therapeutic Products Act, SR 812.21
- Swissmedic: Authorisation under Article 13 TPA
- European Medicines Agency: Obtaining an EU marketing authorisation
- Swissmedic: Product information for human medicinal products
- Swissmedic: Requirements of the Responsible Person for Pharmacovigilance
- Federal Office of Public Health: Prices of medicines in Switzerland
Independent editorial information for business planning. This is not regulatory or legal advice. Current official guidance prevails; any external specialist introduction is discussed with you first. Please do not send patient data or confidential dossiers.
Free first review
Map the Swiss gaps after your EU authorisation
Send a non-confidential summary of your company, product stage and specific question. We review your enquiry and discuss any specialist introduction with you first.
